Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fauci: Borrowed Cash Won't Carry Zika Efficacy Trials

Executive Summary

Cash borrowed from various US government programs, including the Ebola response, is enough to get at least two Phase I Zika vaccine trials underway, but those funds won't carry the efficacy studies – the preparations of which must get off the ground next month. So Congress needs to allocate new dollars within the next few weeks or the Phase II trials will be in jeopardy, Anthony Fauci, the nation's top infectious disease official, told Scrip.

Advertisement

Related Content

Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract
Emerging Diseases: Disruptive, Commercially Risky, But GSK Has A Solution
Zika Funds Stuck In Political Fight; Vaccines Continue On Borrowed Cash
Zika $1.1bn Republican Funding Deal Reached; White House, Dems Condemn
Congrats, Your Vaccine Works; Now, Who Will Buy It?
Fauci: 'Trust Us' Won't Fly With Pharma On Zika Funds
Robbing Ebola To Pay For Zika: Playing With Fire?
Serious About Zika, Obama Seeks $1.8bn To Combat Virus

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065580

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel